Neurologic Drugs : Anesthesia
TULTA1 “Ultane liquid” 250 ml/bot
適應症：吸入性全身麻醉劑。
Usual dose:
General anesthesia: 0.5-3% concentration with or without concomitant use of nitrous oxide.
Dose adjustment:
Geriatric: minimum alveolar concentration (MAC) decreases with increasing age; average concentration of sevoflurane to achieve MAC in 80 year old is approximately 50% of that required in a 20 year old.
With nitrous oxide: anesthetic requirement for sevoflurane is decreased when administered in combination with nitrous oxide; using 50% nitrous oxide, the minimum alveolar concentration (MAC) is reduced approximately 50% in adults and approximately 25% in pediatric p’ts.
Contraindiction:
Malignant hyperthermia, known or suspected susceptibility; sevoflurane may trigger reaction.
Precaution:
KOH containing CO2 absorbents, concomitant administration; may affect inspired sevoflurane concentration volume.
Pediatric p’ts; potentially fatal hyperkalemia has been reported; risk increases with concomitant administration of succinylcholine, and in p’ts with latent or overt neuromuscular disease (especially Duchenne muscular dystrophy).
Renal insufficiency (serum creatine > 1.5 mg/dL).
Underlying hepatic conditions or concomitant treatment with drugs known to cause hepatic dysfunction; may increase risk of post-operative hepatic dysfunction or hepatitis with or without jaundice.
Adverse effect:
Common: nausea, vomiting, agitation.
Serious: bradyarrhythmia, hypotension, tachyarrhythmia, malignant hyperthermia, hepatic necrosis, liver failure, seizure, laryngeal spasm, respiratory depression.